Related Experiment Video
Updated: Aug 26, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C
P E Golstein1, M L Delforge, J Deviere
1Department of Gastroenterology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. pgolstei@ulb.ac.be
Abstract:
There is no standard approved treatment for acute hepatitis C and the combination of pegylated interferon-alpha and ribavirin, currently recognized as the standard of care for chronic hepatitis C, has not been evaluated for acute hepatitis C. Adverse events induced by interferon therapy are numerous but myopathy is rare and has not been described with the use of pegylated interferon-alpha. We report the case of a 33-year-old Caucasian man who was successfully treated for acute hepatitis C with the combination of pegylated interferon-alpha2b and ribavirin, and who during treatment developed myopathy which proved reversible.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Hepatitis
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Hepatic Encephalopathy
